Marks offered his resignation while citing Kennedy’s “misinformation and lies” and an “unprecedented assault on scientific truth” impacting public health.

As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center for Biologics Evaluation and Research,

Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary Robert F. Kennedy Jr. on vaccines. Moderna’s stock dropped 9%, while Vaxcyte’s plummeted 46% (though shares of Vaxcyte were also affected by disappointing results of a vaccine candidate.)

The Food and Drug Administration’s chief tobacco regulator has been forced out. Brian King's departure Tuesday comes just days after the FDA's top vaccine official stepped down over disagreements with Health Secretary Robert F.

Steele, who joined the FDA in 2022, was previously senior adviser at the Center for Biologics Evaluation and Research, which regulates biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies.

Commissioner Marty Makary signed off on the plan to push out the agency’s top vaccine official, Peter Marks, in one of his first acts as chief,

The top vaccine official with the Food and Drug Administration has resigned and criticized the nation's top health official for allowing “misinformation and lies” to guide his thinking behind the safety of vaccinations.

The pharma and biotech sector has been under pressure since Donald Trump returned to the White House earlier this year.